and prescription drugs
Professional content for visitors with qualification in medicine or pharmaceuticals This content is only accessible by using your personal password.Learn more
Our products are available in 65 countriesClick here to learn more
Our activities incorporate all areas in the pharmaceutical value chainClick here to learn more
One of the fundamental pillars of our strategy is innovation. We devoted EUR 47 million to research and development in the 2018/2019 financial year.Click here to learn more
CEO of Egis was granted the award ‘For the Hungarian Economy’
Egis tied as the most popular employer for science students and young graduates and early-stage professionals, found a new study analysing the preferences of young employees and graduates.
As research and development are fundamental pillars of our strategy Egis is deeply committed to raise students’ interest in science and help the promising young minds develop their talents. That is why we have been supporting the annual ’Scientific and Innovation Talent Recruitment Contest for Youth’ for decades. This year, Egis’ prize went to undergraduate student Hunor Sebők.
The quality of life of millions depends on the availability of our medicines, as Egis sells the most boxes of medicine in Hungary. Hungarian doctors most often choose Egis medicines particularly for the therapy of cardiovascular diseases, which is a common disease. Our medicines provide therapeutic solutions for the diseases cardiovascular diseases (38%), for the illnesses of the central nervous system (17%) and respiratory system (10%), further 10% are cancer treatment and immunotherapeutic drugs. Taking these medicines continuously is essential for maintaining the patients’ quality of life and for the success of the therapy.
The Semmelweis University and Egis Pharmaceuticals PLC have agreed on an even closer cooperation than before. Our common goal is to further raise the standards of pharmaceutical R+D as well as pharmacist and doctor training by making use of the synergies in each other’s activities. As a result of the agreement, new health industrial innovations can be launched and the Semmelweis University can be extended with more practical educational and training elements that also meet the needs of the Hungarian pharmaceutical industry.
Egis’ products are available in 65 countries. Our portfolio consists of 629 products. Our main focus lies on treating diseases of the cardiovascular and central nervous systems.Learn more about our products